Human Immunoglobulin G [EPC]

24 marketed 39 in Phase 3 1 in Phase 2

This page covers all Human Immunoglobulin G [EPC] drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Fc receptors and complement system (indirect mechanism via antibody delivery), Fc receptors, complement system, pathogenic antigens and antibodies, Human thymocytes and T lymphocyte surface antigens (CD2, CD3, CD4, CD8, HLA-DR).

Targets

Fc receptors and complement system (indirect mechanism via antibody delivery) · Fc receptors, complement system, pathogenic antigens and antibodies · Human thymocytes and T lymphocyte surface antigens (CD2, CD3, CD4, CD8, HLA-DR) · Hyaluronic acid in subcutaneous tissue; immunoglobulin G replacement · Multiple pathogenic antigens (polyvalent) · Rabies virus glycoprotein · Fc receptors, pathogenic antigens and antibodies · Fc receptors and complement system (via IgG antibodies) · Digoxin (cardiac glycoside) · Respiratory syncytial virus (RSV) surface proteins

Marketed (24)

Phase 3 pipeline (39)

Phase 2 pipeline (1)

Patent intelligence